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Abstract
Background: The effect and safety of catgut implantation at acupoints o treat allergic rhinitis (ICD-10 code J30.4)
remain controversial. Here, we used a sham catgut implantation group to determine whether catgut implantation
at acupoints is an effective and safe treatment for allergic rhinitis.
Methods: A randomized double-blind clinical trial, with parallel groups was conducted. Skin prick and puncture
test (SPT) was performed to confirm the diagnosis before enrollment. The participants received two sessions of
treatments of active or sham catgut implantation at acupoints (once every two weeks) with a follow-up phase of
8 weeks. The visual analogue scale (VAS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were used to
determine the severity of allergic rhinitis. The use of anti-allergic medication was used as a secondary indicator.
The incidence of adverse events was also recorded and analyzed.
Results: An improvement of the VAS and RQLQ scores was observed in both the active and sham-controlled group
sat four and eight weeks after the treatment in the self-control analysis. Comparison revealed no significant difference
between the treatment and sham-controlled groups until 8 weeks after the 2-week treatment regimen (t = −2.424,
P = 0.017). However, the RQLQ scores significantly differed between the two groups after 4 weeks of treatment
completion (t = −2.045, P = 0.05) and this difference lasted until the end of 8-week follow-up (t = −2.246, P = 0.033).
Throughout the treatment regimen, none of the participants took any relief medication, and no severe
adverse events occurred.
Conclusion: Our findings suggest that catgut implantation at acupoints is an effective and safe method for
symptomatic treatment of allergic rhinitis.
Trial registration: Chinese Clinical Trial Registry ChiCTR-TRC-12002191 (Date of Registration: 2012-05-09)
Keywords: Allergic rhinitis, Catgut implantation at acupoints, Randomized controlled trial
Background
Allergic rhinitis (ICD-10 code J30.4) is a symptomatic
disorder of the nose triggered by allergens such as house
dust mites, pet dander, or pollen. Allergic rhinitis has be-
come a major health problem worldwide and affects a
substantial number of people. The Allergic rhinitis and
its impact on asthma (ARIA)2008 document estimated
that over 600 million patients from all countries, all
ethnic groups, and of all ages suffer from AR [1]. An epi-
demiological study in 11 major Chinese cities reported
that the prevalence of allergic rhinitis has increased to
24.6 % in 2007 [2]. Although allergic rhinitis comprises
the classic symptoms of sneezing, rhinorrhea, and nasal
obstruction, it is associated with impairments of patient
function in day-to-day life. Patients with allergic rhinitis
may also suffer from sleep disorders, emotional
problems, and impairment in activities and social func-
tioning [3].
Pharmaceutical care is an optimal strategy for the
management of allergic rhinitis. A stepwise medical
treatment was proposed in the ARIA workshop report
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[1]. However, not all the patients’ symptoms can be con-
trolled with pharmacological treatment. Treatment based
on guidelines is not effective in all patients [4]. Around
one-third of patients with moderate/severe symptoms are
uncontrolled despite optimal pharmacologic treatment
[1]. Complementary/alternative treatment is now being
extensively used for allergic rhinitis and appears to yield
satisfactory results [5]. Among these interventions, acu-
puncture is widely accepted as an easily available and af-
fordable treatment choice in China and other countries, to
relieve the symptoms of AR [6–10]. Catgut implantation
at acupoints is a subtype of acupuncture. In this treat-
ment, approximately 1- to 1.5-cm-long catgut is embed-
ded in the acupoint by a special needle. The catgut can be
completely absorbed by the tissue in 2–4 weeks. Then, the
continuous stimulation caused by the catgut at the acu-
point produces a therapeutic effect. Therefore, catgut im-
plantation at acupoints may help treat chronic diseases
such as AR [11–13].
We carried out a systematic review in order to assess
the effectiveness and the possible adverse effects of cat-
gut implantation at acupoints for allergic rhinitis [14]. In
this review, due to the methodological shortcomings and
risk of bias of the included trials, limited evidence
showed that catgut implantation can be used to treat
allergic rhinitis. There is an urgent need for robust ran-
domized clinical trials (RCTs) with high quality and lar-
ger sample size in this field.
Therefore, we undertook a randomized, double-blind,
large-scale study to evaluate the effectiveness of catgut
implantation in adults with allergic rhinitis. This study
has been approved by the Sichuan Regional Ethics
Review Committee on Traditional Chinese Medicine
(ethics approval number, 2012KL-002). The work re-
ported in this article has been registered with an identi-
fier (ChiCTR-TRC-12002191) by the Chinese Clinical
Trial Registry.
Methods
A detailed description of this double-blinded random-
ized clinical trial with two parallel groups (described as
“treatment group” or “sham-controlled group” res-
pectively) has been previously published [15]. This study
protocol followed the guidelines for clinical research on
acupuncture (WHO Regional Publication, Western Pa-
cific Series No.15, 1995) and both the recommendations
of Consolidated Standard of Reporting Trials [16] and
Standards for Reporting Interventions in Clinical Trials
of Acupuncture [17]. The protocol was approved by the
Sichuan Regional Ethics Review Committee on Trad-
itional Chinese Medicine, and the ethics approval number
of 2012KL-002. The work reported in this article was reg-
istered with an identifier (ChiCTR-TRC-12002191) by
Chinese Clinical Trial Registry.
Participant inclusion criteria
The clinical diagnostic criteria published by ARIA in
2008 [1] was used to assess the eligibility for participa-
tion with AR in this study. The diagnosis of allergic
rhinitis was based upon the concordance between a typ-
ical history of allergic symptoms and diagnostic tests.
Typical symptoms of allergic rhinitis included rhinor-
rhea, sneezing, nasal obstruction, and pruritus. Prick and
puncture tests were used for the diagnosis of specific al-
lergies. Subjects were included if they met the following
inclusion criteria:
(1)Patients aged between 18–70 years
(2)Those not participating in any other clinical trial
(3)Those with no previous experience of catgut
implantation at acupoints
(4)Those who provide written informed consent
(5)Those presenting with typical symptoms of AR,
such as rhinorrhea, sneezing, nasal obstruction,
and pruritus. These symptoms should last more
than one hour on most days.
Some patients may have ocular symptoms due to
outdoor allergens.
(6)Those with positive skin prick and puncture test
performed by trained health professionals.
Standardized vaccine (Alutard SQ, ALK- Abelló,
Denmark) was used in the prick and puncture test.
Oral H1-antihistamines are not permitted before
the skin test. Skin prick tests should be read at the
peak of their reaction by measuring the wheal and
flare approximately 15 min after the performance
of the test.
Exclusion criteria
Patients with any of the following conditions were
excluded:
(1)Pregnant women or women who were ready to
conceive in the past six months, or lactating women
(2)Patients who were receiving immune therapy
(3)Patients with other allergic diseases such as
bronchial asthma or allergic purpura
(4)Patients with nasal polyposis
(5)Patients with heterologous protein allergy
(6)Patients with other organic disorders such as AIDS,
vascular malformation, hypertension, hematologic
diseases, diabetes mellitus, malignant tumor, or
mental disorders
Recruitment
Participants were enrolled either by the recruiting hos-
pital when they came to our otorhinolaryngology clinics
to seek therapy or by the printed recruitment posters in
the hospital and the campus of Chengdu University of
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Traditional Chinese Medicine. Patients who satisfied the
inclusion criteria and were willing to participate in the
trial were recruited.
Randomization and blinding
A random allocation sequence was generated by Excel
(Microsoft Office) random number generator (Microsoft,
USA). Patients were assigned to either the real catgut
implantation group or the sham-controlled one in 1:1
ratio by computer program. The random numbers were
sealed in opaque envelopes. Participant who met the in-
clusion criteria was asked to pickup one of the enve-
lopes. They were randomized into either the study or
control groups depending on the random number that
was in the envelope. At the same time, the correspond-
ing randomization information of the participant was
collected, which included the participant’s name in Pin-
yin format, the participant’s numerical birthday and gen-
der. All this information was recorded in duplicate and
sealed in opaque envelopes. These opaque envelopes
were preserved separately by the principal investigator
and the primary sponsor. The envelopes were all kept
intact until the blinding was removed. Participants, re-
searchers, and study physicians who interviewed and re-
cruited patients were blinded to the group assignments.
For the sake of the specialty of the treatment of acu-
puncture, the acupuncturists were not blinded during
the study. However, they were allowed to neither com-
municate with the participants about the treatment nor
participate in the assessment of study outcomes.
The two groups were designated A (real treatment
group) and B (sham-controlled group) in the medical re-
cords and case report forms. All information was locked
out and saved in a database. Blind exposure was not pro-
vided until the statistical analysis was complete. Then
two opaque envelopes containing the random allocation
tables were unsealed by the principal investigator and
the primary sponsor simultaneously to determine which
groups the participants belonged to.
Procedures
A total of 128 participants who were found eligible for
inclusion and provided their written informed consents
to participant in the study wereassigned into one of the
two study arms according to the random numbers of
computer-generated allocation sequences, including the
sham-control group consisting of patients who would re-
ceive a placebo treatment. After completing the baseline
measures, both groups received real or sham catgut im-
plantation at acupoints once per two weeks. Each patient
had 2 treatment weeks and 8 weeks of follow-up. Figure 1
illustrates the flowchart of this study. The intervention
was designed according to the documentary records in the
ancient books and was consistent with both the Standards
for Reporting Interventions in Controlled Trials of
Acupuncture (STRICTA) guidelines for the performance
of acupuncture studies [18] and the World Health
Organization (WHO) standard acupuncture point loca-
tions in the Western Pacific Region Geneva ( WHO,2008)
[19]. Both the real and sham catgut implantation was per-
formed by the same acupuncturist throughout the study.
Acupuncturists should have undergone at least 8 years of
acupuncture training and be qualified TCM doctors.
Intervention
Five acupoints were selected for this research on the
basis of our previous study [20]. For the first treatment,
three acupoints were used for each patient. They were
Yingxiang (LI20), Yintang(EX-HN3), and Hegu(LI4). For
the second treatment, Zusanli(ST36) and Quchi(LI11)
were chosen (Fig. 2). The acupoints were the same in
both the treatment groups. All the treatments were per-
formed by the same registered acupuncturists to ensure
participant blinding and consistency of treatment.
To locate the acupoint [21]:
Hegu (LI4): abduct thumb and index figure, the point
is located at the middle point between the web and
the junction of the first and second metacarpal bones.
Quchi (LI11): with the elbow flexed, the point is
located at the end of the cubital crease.
Yingxiang (LI20): in the nasolabial groove, beside
the midpoint of the lateral border of the ala nasi.
Yintang (EX-HN3): on the forehead, at the midpoint
between the eyebrows.
Zusanli (ST36): on the anteriolateral side of the lower
leg, 3 cun inferior to Dubi (ST35), one finger breadth
(middle finger) lateral to the anterior crest of the tibia.
(Dubi-ST35: with the knee flexed, the point is located
on the knee, in the depression internal to the patella
and the patellar ligament.)
Participants received one session of real or sham cat-
gut implantation at acupoints once every two weeks.
Subjects were advised to lie supine. The pulse rate, blood
pressure, and oxygen saturation were monitored rou-
tinely during the procedure as a precautionary measure.
In both groups, swabs with 75 % alcohol and dry sterile
cotton wool were used when withdrawing the needles.
Pre-sterilized disposable needles (9#, Hanjiang Guoxiang
Medical Appliance Factory, Yangzhou, China) and cat-
guts (000, Pudong Jinhuan Medical Products Co., Ltd.,
Shanghai, China) were used for the treatment. For
Yintang (EX-HN3), the needle was inserted to a depth
of 1.0 cm downward to the nose in a horizontal direc-
tion with respect to the skin. For Yingxiang(IL20), the
penetration was 2.0 cm in an oblique direction along
the nasolabial sulcus towards the root of the nose with
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respect to the skin. For Hegu, Zusanli, and Quchi, the
penetration was 2.5 cm, and carried out in a perpen-
dicular direction with respect to the skin (Table 1).
Twirling, lifting, and thrusting of the needle were per-
formed. After treatment, the skin of the acupoints
should not be touched with water or any cosmetics for
three days.
Needle used for catgut implantation was made up of
two parts: the internal blunt stylet and the external can-
nula with a sharp pinhead which ensured that the can-
nula could puncture the skin. These two parts made the
needle similar to a kind of trocar. In real catgut embed-
ding, the internal stylet should be withdrawn from the
cannula for about 1.5 cm. Then a 2- to 3-mm catgut was
placed into the cannula from the side of the pinhead.
When the needle is inserted into the acupoints with
proper depth, the catgut was pushed into the tissue of
the acupoint by the stylet (Figs. 3 and 4).
For sham catgut implantation, the whole therapeutic
procedure was the same as that in the real group, with
the same acupoints, the same needles, and the standard
techniques. However, only the sham treatment group
did not contain catgut was not present in the cannula in
the sham treatment. Without the catgut embedded in
acupoints, patients in this group received just the stimu-
lus of needling. To ensure the blinding, acupuncturists
were instructed not to communicate with the partici-
pants throughout the duration of the treatment.
In both groups, patients were permitted to use chlor-
pheniramine when needed. The use of chlorpheniramine
(dosage, frequency, and period of treatment) should be
recorded as relief medicine scores.
Fig. 1 Flowchart
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Clinical evaluation
Primary outcome
Visual analogue scale (VAS) [22] and Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ) [23, 24] were used
to evaluate the severity of the symptoms of allergic rhin-
itis at week 0 (baseline) and at weeks 2 and 8. In VAS,
the influence of the presenting symptoms of allergic
rhinitis on each participant was evaluated. The symp-
toms were classified as mild, moderate, or severe based
on the total VAS score (0–10 cm: mild, VAS 0–3; mod-
erate, VAS 3.1–7; severe, VAS 7.1–10).
RQLQ was also used to assess the disease-associated
problems of the participants in seven aspects of daily life:
activities, sleep, non-nose/eye symptoms, practical prob-
lems, nasal symptoms, nose symptoms, and emotional
symptoms. The score of each of the item was graded into
0–6. The total score of the seven items was calculated for
every participant at baseline and at weeks 4 and 10.
Secondary outcome
Relief medication scores and adverse events were evalu-
ated as the secondary outcome. Participants were asked
to complete diaries in the baseline and every two weeks
after randomization. In the diaries, the participants
recorded if H1-blocker (chlorpheniramine) had been
taken during the treatment period, including the dosage
and time of medication. In addition, adverse events (e.g.,
numbness, hematoma, local infection of the acupuncture
sites, headache, fainting, and serious pain) were also re-
corded during the treatment and follow-up phases.
Statistical analysis
The sample size was estimated from equations and our
preliminary study. An improvement of no less than 25 % of
the treatment group compared with the sham-controlled
one was suggested. With participants recruited in the two
groups in a 1:1 ratio, the following formula was used to
estimate sample size [25]:









In the formula, n1 and n2 represent the sample size of
each group. π1and π2are the overall rates of each
sample. πc = (π1 + π2)/2, α = 0.05, Z0.05 = 1,96, β = 0.10,
Z0.10 = 1.282. Statistical analysis was performed using
5 % significance and 90 % power, resulting in an esti-
mated 64 patients per group.
Fig. 2 Locations of selected acupoints (for both of the groups)
Table 1 Acupoints and manipulation in both the real and sham groups
Weeks for treatment Acupoints Angle and direction Depth
Week 1 Yintang(EX-HN3) (unilateral) Downward to the nose in a horizontal direction with respect to the shin 1.0 cm
Yingxiang(LI20) (both) In an oblique direction along the nasolabial sulcus towards the root of
nose with respect to the skin
2.0 cm
Hegu(LI4) (both) Perpendicular direction with respect to the skin 2.5 cm
Week 2 Zusanli(ST36) (both) Perpendicular with respect to the skin 2.5 cm
Quchi(IL11) (both) Perpendicular direction with respect to the skin 2.5 cm
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To assess the baseline characteristics of the two
groups, unpaired t test or x2 test was used. In comparing
the efficacy of real catgut implantation with the sham
one, the chi-square test was used for analysis of categor-
ical data. Measurement data were analyzed using the in-
dependent sample test or Kruskal-Wallis H Test. For
non-normally distributed data, Wilcoxon rank-sum test
was used. Statistical analysis was performed with SPSS
software version 19 (SPSS Inc., Illinois) and the values
were considered statistically significant at P <0.05. Stat-
istical analysis was carried out in a blinded manner by
qualified statisticians.
An intention-to-treat (ITT) analysis of the results was
conducted based on the initial treatment assignment.
Participants who strayed from the protocol (for instance,
by not adhering to the prescribed intervention, or by
withdrawing from the study due to adverse event or
other reasons) should still be kept in the analysis. The
missing data were supplemented with those obtained
recently before the participant was lost to follow-up. A
complete outcome data was performed for all random-
ized subjects.
Patient safety
Before randomization, the participants were asked to
take routine blood, urine, liver function, blood glucose,
and kidney function tests to exclude any related serious
illness. When any adverse effect occurred, proper med-
ical treatment should be given as soon as possible.
Quality control
All acupuncturists were experienced in the technique for
catgut implantation, and how to deal with adverse
events. The acupuncturists also received training on
how to communicate with participants and how to keep
them blind to the treatment throughout the trial.
In order to maintain the quality of this trial, audits
were conducted regularly on compliance with standard
Fig. 3 Needle used for the treatment
Fig. 4 Insert the catgut into the cannula of the needle
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operation procedures every week, and the reports of the
audits were presented to the chief monitor. The database
was locked as soon as the data was input. All the case
report forms (CRF) in paper version were properly
maintained by the investigator. The reason of withdraw-
ing or loss of follow-up of any of the participants should
be clarified, and the rate should be statistically analyzed.
Results
Participant characteristics at baseline
A total of 128 participants with AR were recruited and
randomly assigned to the active catgut implantation
group or the sham-controlled group in a 1:1ratio. Only
two of the patients were unable to complete the 2-week
treatment. In the follow-up period, another six cases
dropped out. The main reasons for the withdrawals or
dropouts are listed in Table 2.
No significant differences were identified between sub-
jects in either group regarding age, gender, underlying
health status, RQLQ score, VAS score and TCM syn-
drome type on baseline (Table 3)
Primary outcome
For the analysis based on VAS scores, the difference be-
tween the treatment group and the sham-controlled
group was not significant until 8 weeks after the 2-week
treatment regimen (t = −2.424, P = 0.017; Table 4). How-
ever, the RQLQ scores between the two groups after
2 weeks of treatment completion significantly differed
(t = −2.045, P = 0.05), and this difference could be ob-
served until the end of the 8-week follow-up (t = −2.246,
P = 0.033).
In the self-control study, the efficacy of the active
treatment and sham groups was evaluated. The results
indicated a significant improvement in the VAS and
RQLQ scores of both the groups at weeks 4 and 8 after
the treatment regimen when compared with the respect-
ive baseline scores. These differences are illustrated in
Table 5.
Secondary outcome
None of the participants took H1blockers (chlorphenir-
amine) as relief medicine.
No adverse events occurred that necessitated with-
drawal of participants from the trial. The reported events
included minor discomfort at the needling sites and sub-
cutaneous induration (Table 6).
Discussion
This study evaluated the effects of catgut implantation at
acupoints of allergic rhinitis in two parallel samples. The
results showed that both the real and sham treatments
were effective for alleviating the symptoms of allergic
rhinitis and improving the quality of the life of the par-
ticipant. However, the VAS and RQLQ scores did not
improve until week 4 of the interventions, suggesting
that the regulatory effect of the treatments for allergic
rhinitis appeared slowly. Second, the VAS and RQLQ
scores between the two groups significantly differed
from the baseline after 4 or 8 weeks of treatment com-
pletion. Twelve weeks after the end of the treatment, the
decreases from baseline in the TNSS (total score for the
four symptoms) was greater in the treatment group than
in the sham group. The improvement in the TNSS and
RQLQ with treatment and the persistence of the effect
appear to be the most clinically significant findings of
the study.
To our knowledge, no other randomized controlled
trial of catgut implantation has been reported in English,
although many recent reports in Chinese literatures have
reported the efficacy of this intervention for allergic
rhinitis. Catgut implantation is a subtype of acupuncture
that can extend the sensation of needling because of the
persistent stimulus to acupoints caused by the embed-
ded catgut. Furthermore, catgut implantation has an ef-
fect which is similar to pricking blood therapy. It was
found to have a therapeutic effect for chronic diseases
by dredging the channels, invigorating the pulse, and
regulating the qi and blood. Our study demonstrates
positive outcomes of both active and sham catgut im-
plantation for allergic rhinitis. Although no catgut was
embedded in the acupoints in the patients receiving
sham treatment, the penetrating of the needles produces
a therapeutic stimulation similar to that in conventional
acupuncture. The external diameter of the needle (9#)
used in the treatment is approximately 0.9 mm, which is
larger than that used in acupuncture. The thicker the
Table 2 Reasons for withdrawal or dropout
Group A (Active treatment group) Group B (Sham-controlled group)
Patients lost to
follow-up





1 Not adhering to the prescribed intervention 1 Not adhering to the prescribed intervention
During follow-up
(weeks 2–10)
2 Too busy to complete follow-up 1 Too busy to complete follow-up
1 Admitted to the hospital for appendectomy 2 Went abroad for business or tour
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needle, the greater is the intensity of stimulation. There-
fore, the participants in the controlled group received
both the acupuncture stimulus and pricking blood ther-
apy. This might explain the improved scores of VAS and
RQLQ in the sham-controlled group. However, the im-
provements in the sham group were inferior at weeks 4
and 8 after treatment compared to the treatment group.
This difference might be due to the slow but lasting
stimulation of catgut implanted at the acupoints.
Deciding on an appropriate control procedure for clin-
ical studies on catgut implantation at acupoints is a par-
ticular challenge. For the clinical trial of acupuncture,
two approaches for sham-controlled treatment have
been to use non-penetrating needles [26, 27] or needles
inserted shallowly 1–2 cm away from the defined acu-
points [28, 29]. Based on the special structure of the
needle for catgut implantation, we found that the best
approach for the sham treatment was to insert needles
at the same acupoints with the same acupuncture ma-
nipulation but without embedding catgut. The difference
between the two groups depended on whether or not
the catgut was embedded. Consistent with the findings
of our previous study on catgut implantation for allergic
rhinitis, we found that the participants could be blind
adequately by this approach. The sham treatment may
have unspecific physiological effects of needling or just
have placebo effects. In both groups, minor and minimal
adverse events occurred only in a few cases, none of
which were serious and did not result in participant
withdrawal from the trial.
In our study, five acupoints were chosen for the treat-
ment: Yintang (EX-HN3), Yingxiang (LI20),Zusanli (ST36),
Table 3 Subject characteristics
Group A (Active treatment group) Group B (Sham-controlled group) Statistics P value
Age (years) 36.112 ± 11.495 38.083 ± 12.106 T = 1.047 0.297
Gendera (males/female) 29/35 36/28 x2=1.532 0.216
Weight (kg) 60.391 ± 9.407 59.817 ± 8.697 t = 0.177 0.860
Height (cm)b 166.031 ± 6.575 164.752 ± 6.731 U = 1854.5 0.356
Pulse (beats/min)b 75.828 ± 6.870 77.297 ± 6.004 U = 1788.000 0.214
EO (109/L)b 0.201 ± 0.132 0.195 ± 0.139 U = 1952.000 0.647
AST (U/L) 28.141 ± 7.322 29.672 ± 9.952 t = −0.991 0.324
ALT (U/L) 21.656 ± 6.393 23.125 ± 6.646 t = −1.274 0.205
BUN (mmol/L)b 4.572 ± 1.540 4.988 ± 1.325 U = 1804.000 0.245
Crea (μmol/L)b 53.367 ± 11.068 56.094 ± 9.018 U = 1726.520 0.125
RQLQ score 83.933 ± 10.076 88.801 ± 8.872 t = −1.405 0.171
VAS scoreb 7.036 ± 1.839 6.648 ± 1.379 U = 1739.500 0.136
TCM syndrome typea (number of patients) x2=1.030 0.794
Insufficiency of the Spleen-qia 25 23 – –
Insufficiency of the Lung-qia 23 26 – –
Insufficiency of the Kidney-yanga 9 6 – –
Retention of the Pathogenic Heat of the Lunga 7 9 – –
RQLQ Rhinitis Quality of Life Questionnaire, VAS Visual Analogue Scale
For each variable except gender and TCM syndrome type, the values are expressed as the means ± SD
aChi-square test
bWilcoxon rank-sum test for the non-normally distributed data
The categories without aor bwere analyzed with t test
Table 4 Results on RQLQ and total VAS scores between the two groups (means ± SD)
Total VAS score RQLQ score
T1 T2 T3 T1 T2 T3
Treatment group (n = 64) 7.036 ± 1.839 5.302 ± 1.86 3.75 ± 1.93 83.933 ± 10.076 78.67 ± 8.57 73.73 ± 10.48
Sham-controlled group (n = 64) 6.648 ± 1.379 5.204 ± 1.72 4.535 ± 1.724 88.801 ± 8.872 84.471 ± 6.883 79.807 ± 6.221
Statistical analysis U = 1739.500 t =0.324 t = −2.424 t = −1.405 t = −2.045 t = −2.246
P value 0.136 0.751 0.017 0.171 0.050 0.033
T1, baseline at subject recruitment
T2, 2 weeks after intervention
T3, 8 weeks after intervention
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Hegu (LI4), and Quchi (LI11). The selection of acupoints
was guided by Chinese traditional medicinal theory. In
traditional acupuncture theories, allergic rhinitis is stated
as Biqiu, which is in close correlation with the Taiyin lung
meridian of hand and Yangming large intestine meridian of
hand. Thus, the most frequently used specific acupoints
for these two meridians would be selected in this trial
according to a previous review of ancient and modern
literature. The ancient Chinese also believed that
Yangming is a meridian abundant of blood and Qi and
is the acquired foundation. Four of the five acupoints
selected in the study are on the Yangming Meridian,
namely, Yingxiang (LI20),Zusanli (ST36), Hegu(LI4),
and Quchi (LI11). Hegu(LI4) is the source-point of the
large intestine meridian of the hand. Qi of the visceral
is input at this point. Based on the theory in TCM, the
lung opens at the nose and the large intestine which
are interior-exteriorly related. Therefore, Yingxiang
(LI20) and Hegu (LI4) are important acupoints for im-
proving lung air (qi) deficiency syndrome. Zusanli (ST36)
and Quchi(LI11) are sea points of Yangming large intes-
tine meridian of the hand and Yangming stomach merid-
ian of the foot. These acupoints are used to fortify the
spleen and replenish the Qi. At the same time, stimulation
of these points could reinforce earth to generate metal
and regulate asthenia-cold in the remission stage of aller-
gic rhinitis.
On the other hand, the nose is an orifice with lucid
Yangin traditional Chinese medicine. Lucid Yang is
confluent at the acupoints of Yingxiang (LI20) and
Yintang(EX-HN3). These two acupoints are on the me-
dian line of the face and play an important role in
clearing the nasal passages. In addition, Yingxiang
(LI20) is considered a specific point on the Yangming
large intestine meridian of the hand. In our previous
trial, it has been suggested that symptoms of allergic
rhinitis could be effectively alleviated by embedding
catgut at these acupoints.
Not many studies have investigated the mechanism of
catgut implantation at acupoints. We explored the prob-
able mechanism focusing on neurogenic inflammation.
Some studies have demonstrated that nerve stimulation
could induce leukocyte activation and plasma extravasa-
tion, which is termed neurogenic inflammation [30, 31].
Based on this theory, we speculated that catgut implant-
ation at acupoints might stimulate the sensory nerve
and regulate the neuropeptide-mediated airway smooth
muscle constriction and decrease vascular permeability
of the nose. Our results showed that there was signifi-
cant decrease in neuropeptides such as substance P (SP),
neurokinin A (NKA), and calcitonin gene-related pep-
tide (CGRP) in the nasal mucosa of catgut implantation
group [32]. Hematoxylin-eosinstaining (HE) staining re-
vealed that edema of the nasal mucosa was alleviated
and the number of inflammatory cells decreased in the
treatment group. This might be a preliminary attempt to
understand the mechanism of acupuncture with catgut
in the treatment of allergic rhinitis. Further studies are
needed to elucidate the effective relationship stimulation
for this treatment.
In our study, participants were permitted to take
chlorpheniramine as relief medicine when they con-
sidered it necessary. As a first-generation oral H1-
antihistamine, chlorpheniramine has been used to treat
allergic diseases for a long time. In recent decades, it has
not been recommended as the first-line medicine for al-
lergic rhinitis as second-generation drugs are available
and because of its sedative and anticholinergic effects. In
our study, we desired to use short-acting relief medica-
tion that would not have a lasting effect and would only
last until the participant could endure the symptoms of
allergic rhinitis and stopped taking the medicine. Com-
pared with other first-generation H1-antihistamines,
chlorpheniramine has the weakest influence on the cen-
tral nervous system and cardiovascular system. Further-
more, the peak concentration of this drug in plasma is
Table 5 Efficacy of the active and sham-controlled groups in
the self-control study
Group A GroupB
VAS RQLQ VAS RQLQ
T2-T1 Statistical t value 9.887 4.314 12.599 5.951
P value P < 0.001 0.001 P < 0.001 P < 0.001
T3-T1 Statistical t value 13.153 6.287 13.659 5.892
P value P < 0.001 P < 0.001 P < 0.001 P < 0.001
T1, baseline at subject recruitment
T2, 4 weeks after intervention
T3, 8 weeks after intervention
Table 6 Reported events associated with real and sham treatment participants
Group Cases Adverse events Degree Measurement Prognosis of the adverse events
Group A 3 Subcutaneous induration the size of
a grain of rice at Yingxiang(LI20) or
Yintang(EX-HN3)
Mild Hot-wet compression at the acupoint The subcutaneous induration
gradually disappeared 2–4weeks
after the treatment
1 Ache in the leg after catgut implantation
at Zusanli(ST36)
Mild Hot-wet compression was applied at the
acupoint 24 h after the treatment
Cured




Hot-wet compression was applied at the
acupoint 24 h after the treatment
Cured
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reached in2.8 ± 0.8 h. The effect lasts 18–24 h. On the
other hand, a longer duration of action-persistence of
clinical effects could be found in second-generation anti-
histamines. In order to minimize the effect of the drug
on the study participants, we selected chlorpheniramine
as the drug of choice. For participant safety, they were
advised not to drive or work at heights or engage in
work involving attention to detail after taking the drug.
Although relief medicine was available as a rescue
method, none of the participants took medication to re-
lieve their symptoms. For most of the participants, the
mean VAS score ranged from 5.2–8.9. In weeks 4 and 8
after treatment, within-group comparison revealed this
score decreased significantly, which indicated that both
real and sham catgut implantation were effective. There-
fore, we believe this is why few participants sought to
take relief medication during the treatment period.
There are many topics in clinical studies on allergic
rhinitis. According to the severity of the disease, a step-
wise treatment was proposed in the ARIA workshop,
which include oral H1-antihistamines, antileukotrienes,
intranasal glucocorticosteroids, intranasal H1-blocker,
decongestant, specific immunotherapy, and so on. How-
ever due to the complexity of AR pathogenesis, multiple
risk factors, pharmacologic treatment is not effective in
all patients. Around one third of patients with moder-
ate/severe symptoms are uncontrolled despite optimal
pharmacologic treatment and some still have severe
symptoms [1].
Catgut implantation at acupoints is one of the external
therapies of TCM, which tries to stimulate certain por-
tions of the body by mechanism stimulation. In fact,
external therapy is also based on the differentiation of a
symptom-complex and the principle behind this treat-
ment is to invigorate or strengthen the automatic reg-
ulation capacity of the body through the meridians and
collaterals.
Although the external therapy is totally different from
conventional medicine, these two types of treatment
should respect and complement each other. Zhou [33]
integrated catgut implantation at acupoints with Lorata-
dine tablet and Budesonide nasal spray to treat several
allergic rhinitis. The result indicated a long-term im-
provement of severity of symptoms and signs of allergic
rhinitis by the therapy. But there are various risks of
biases of this trial, high level evidence could not be
obtained.
Well-designed RCTs needed be conducted to provide
a definitive answer for the combination therapy.
From the long-term perspective, delaying the occur-
rence and progression of AR and establishing an efficient
and practical prevention and control system is the focus
of the future AR research in the world. Possible future
research direction of integrating TCM with western
medication may provide a new space for the develop-
ment of therapy against AR.
Although this is the first robust randomized, double-
blinded large-scale clinical trial of catgut implantation at
acupoints for allergic rhinitis, there are still some limita-
tions. First, only two sessions of treatments were admin-
istrated. The duration of treatment using acupuncture
with catgut is unknown. Thus, it is possible that shorter
durations could have a similar effect, and that longer use
of the treatment or repeated treatments may enhance the
outcome, although further studies are required to verify
this. Second, all participants in this study were followed
up for only eight weeks. Our result just revealed a short-
term efficacy of catgut implantation at acupoints for aller-
gic rhinitis. Further research is still needed.
Conclusion
Based on the efficacy of improving the VAS and RQLQ
scores of allergic rhinitis and minor adverse events, we
concluded that catgut implantation at acupoints may
provide an effective and safe option for the symptomatic
treatment of allergic rhinitis. This study might be the
first to present good clinical evidence of this treatment
in allergic rhinitis.
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